Atea Pharmaceuticals, Inc. (AVIR) intrinsic value & 10-year financials
Atea Pharmaceuticals, Inc. (AVIR) has a Graham intrinsic value of $45.51 per share. At $4.32 on Oct 17, 2026, the stock trades 91% below that value.
- Graham intrinsic value
- $45.51
- Share price (Oct 17, 2026)
- $4.32
- Price vs Graham value
- 91% below
- Market cap
- $352.1M
- Revenue (FY2025)
- —
- Revenue growth (9-yr CAGR)
- 622.5%
- ROIC (10-yr avg)
- -44.4%
- Free cash flow (FY2025)
- —
AVIR 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$158.3M | -$1.94 | — | — | -62.8% |
| FY2024 | — | -$168.4M | -$2.00 | — | — | -49.0% |
| FY2023 | — | -$136.0M | -$1.63 | — | — | -37.8% |
| FY2022 | — | -$115.9M | -$1.39 | -$122.9M | — | -27.9% |
| FY2021 | $351.4M | $121.2M | $1.37 | -$87.0M | 39.4% | — |
| FY2020 | $48.6M | -$10.9M | -$0.13 | $296.7M | -22.7% | — |
| FY2019 | — | -$14.0M | -$0.35 | -$12.8M | — | — |
| FY2018 | — | -$9.1M | — | -$7.9M | — | — |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Atea Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Atea Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -44.4% ROIC.
Atea Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Atea Pharmaceuticals, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $45.51 per share.